Naporafenib

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

2 Sponsors

12 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 1 Phase II: 1 Phase I (Other): 1

Oversight events:

4 temporary halts across 1 trial

View oversight register →

Indications tested

Metastatic malignant melanoma 1 Neoplasm malignant 1

Sponsors using this IMP

Novartis Pharma AG 2 Erasca Inc. 1

All trials

3 total

A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI… Recruiting

2024-511404-17-00 Phase III 10 countries Erasca Inc.
Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended

2024-511934-11-00 Phase II 4 countries Novartis Pharma AG
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Phase I (Other) 8 countries Novartis Pharma AG

Showing 1–3 of 3 trials

← All drugs A–Z